(Washington) Individuals who have received the COVID-19 vaccine from Johnson & Johnson may benefit from a booster dose of a different, messenger RNA vaccine, according to preliminary results from a US study released Wednesday.
The study, funded by the National Institutes of Health (NIH), is eagerly awaited in the United States because it examines the possibility of “mixing” vaccines – that is, using a different vaccine for the disease. Booster dose for beginners only – currently not allowed in the country.
The study was conducted on 458 adults who had been vaccinated with one of the three remedies authorized in the United States (Pfizer, Modernna or Johnson & Johnson) for at least 12 weeks.
These three groups were divided into three new groups, to receive one of the three vaccines available as a booster dose. There were 50 people in each of the nine groups.
The researchers analyzed antibody levels 15 days after the booster dose injection.
In people who were first vaccinated with Johnson & Johnson, antibody levels increased 4-fold after the booster dose of the same vaccine, 35 after the Pfizer booster, and 76 after the modernna booster.
The antibody levels of people who were first vaccinated with Moderna were higher each time than those who were first vaccinated with Pfizer or Johnson & Johnson, “regardless of the vaccine given for the booster dose,” the study said.
Additionally, it stated that “no security issue was detected” after handling the reminders.
The study, which has not yet been peer-reviewed, however, has several limitations.
First, Moderna’s booster dose is 100 micrograms, which is more than double what the company expected for its booster dose.
In addition, the number of participants decreased, and an immune reaction developed beyond the 15 days observed here.
“It’s important not to stay away from these results,” Baylor College of Medicine professor Peter Hotez warned on Twitter. He recalled that the trials on “J&J”‘s second booster dose were “impressive” as the company itself had conducted over a long period of time.
The NIH study should in any case feed the expert committee discussions from the United States Medicines Agency (FDA), which should study the authoritative requests for the booster dose of Moderna and Johnson & Johnson on Thursday and Friday, respectively.
The booster of the Pfizer vaccine has already gained power in the country for certain segments of the population.